Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
A Phase 1 Study of VX-581 in Healthy Subjects and in Subjects With Cystic Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA in healthy participants. The study will also evaluate the safety, tolerability, and pharmacokinetics of VX-581 administered in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581 in healthy participants and in participants with CF. VX-581 will be administered alone and in combination with TEZ and D-IVA. The study consists of Screening Phase, Run-In Phase (CF only), Treatment Phase and Safety Follow-up Phase.
Note: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Medical Information
- Telefonnummer: 617-341-6777
- E-Mail: medicalinfo@vrtx.com
Studienorte
-
-
Kansas
-
Overland Park, Kansas, Vereinigte Staaten, 66212
- Rekrutierung
- Altasciences - Kansas City
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
-
Parts A, B, C:
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)
- A total body weight of more than (>) 50 kg
-
Part D:
- Confirmed diagnosis of CF
Key Exclusion Criteria:
-
Parts A, B, C:
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption
-
Part D:
- History of clinically significant cirrhosis with or without portal hypertension.
Other protocol defined Inclusion/Exclusion criteria may apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Part A: Single Ascending Dose
Participants will be randomized to receive a single dose of VX-581. |
Suspension for Oral Administration. Tablets for Oral Administration. |
|
Placebo-Komparator: Placebo: Part A
Participants will be randomized to receive a single dose of placebo matched to VX-581. |
Suspension for Oral Administration. |
|
Experimental: Part B: Multiple Ascending Dose
Participants will be randomized to receive multiple doses of VX-581. |
Suspension for Oral Administration. Tablets for Oral Administration. |
|
Placebo-Komparator: Placebo: Part B
Participants will be randomized to receive multiple doses of placebo matched to VX-581. |
Suspension for Oral Administration. |
|
Experimental: Part C: VX-581 with TEZ/D-IVA or D-IVA
Participants will be randomized to receive multiple doses VX-581 in combination with TEZ/D-IVA or D-IVA. |
Suspension for Oral Administration. Tablets for Oral Administration. Tablet for Oral Administration.
Andere Namen:
Tablet for Oral Administration.
Andere Namen:
|
|
Placebo-Komparator: Placebo: Part C
Participants will be randomized to receive placebo matched to VX-581 in combination with TEZ/D-IVA or D-IVA. |
Suspension for Oral Administration. Tablet for Oral Administration.
Andere Namen:
Tablet for Oral Administration.
Andere Namen:
|
|
Experimental: Part D: VX-581 with TEZ/D-IVA or D-IVA in CF
Participants with CF will enter a run-in period and receive ELX/TEZ/IVA. Following the run-in period participants will receive VX-581 in combination with TEZ/D-IVA or D-IVA in the treatment period. Following the treatment period, participants will enter a 14-day Washout Period and receive ELX/TEZ/IVA. (Part D will be open-label) |
Suspension for Oral Administration. Tablets for Oral Administration. Tablet for Oral Administration.
Andere Namen:
Tablet for Oral Administration.
Andere Namen:
Fixed dose combination (FDC) Tablets for Oral Administration.
Andere Namen:
Tablet for Oral Administration.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: From Day -1 up to Day 8
|
From Day -1 up to Day 8
|
|
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: From Day -1 up to Day 17
|
From Day -1 up to Day 17
|
|
Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: From Day -1 up to Day 17
|
From Day -1 up to Day 17
|
|
Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: From Signing of Informed Consent up to Day 105
|
From Signing of Informed Consent up to Day 105
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-581
Zeitfenster: On Day 1
|
On Day 1
|
|
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Up to 24 Hours (AUC0-24h) Post-Dose of VX-581
Zeitfenster: On Day 1
|
On Day 1
|
|
Part B: Cmax of VX-581
Zeitfenster: On Days 1, 7, and 10
|
On Days 1, 7, and 10
|
|
Part B: AUC0-24h Post-Dose of VX-581
Zeitfenster: On Days 1, 7, and 10
|
On Days 1, 7, and 10
|
|
Part C: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Zeitfenster: On Days 1, 7, and 10
|
On Days 1, 7, and 10
|
|
Part C: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Zeitfenster: On Days 1, 7, and 10
|
On Days 1, 7, and 10
|
|
Part D: Cmax of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Zeitfenster: On Day 1 and Day 28
|
On Day 1 and Day 28
|
|
Part D: AUC0-24h Post Dose of VX-581, TEZ (if administered), D-IVA and their Metabolite(s)
Zeitfenster: On Day 1 and Day 28
|
On Day 1 and Day 28
|
|
Part D: Absolute Change in Sweat Chloride (SwCl)
Zeitfenster: From Baseline Up To Day 28
|
From Baseline Up To Day 28
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Genetische Krankheiten, angeboren
- Erkrankungen der Atemwege
- Erkrankungen des Verdauungssystems
- Lungenkrankheit
- Säugling, Neugeborenes, Krankheiten
- Erkrankungen der Bauchspeicheldrüse
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Mukoviszidose
- Elexacaftor, Ivacaftor, Tezacaftor -Arzneimittelkombination
- Tezacaftor
- Ivacaftor
- Deutivacaftor, Tezacaftor, Vanzacaftor
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- VX25-581-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .